Western Companies' Perspectives On Emerging Markets: Execution Trumps Strategy - PharmAsia Summit
This article was originally published in PharmAsia News
Executive Summary
SAN FRANCISCO - Western companies expanding in emerging markets are likely to distinguish themselves from competitors by successful execution and understanding of local markets, more so than by broad strategic differences, according to participants on a panel on Big Pharma perspectives on emerging markets at Elsevier Business Intelligence's PharmAsia Summit, held Oct. 26 in San Francisco
You may also be interested in...
Asia Spotlight: India Case Study – Novartis’ Galvus Inches Closer To Merck’s Januvia As Battle For Brand Supremacy Rages On
Three years after Novartis and MSD launched their DPP-4 inhibitors in India, PharmAsia News takes a closer look at who will come out on top.
India Case Study: Novartis’ Galvus Inches Closer To Merck’s Januvia As Battle For Brand Supremacy Rages On
Three years after Novartis and MSD launched their DPP-4 inhibitors in India, PharmAsia News takes a closer look at who will come out on top.
Spectacular Market Launches Key To Enduring Success Of Brands In Asia - IMS Health
Data show that "pharmerging" markets, will grow at 14-17%, while the U.S. will lag with 3-6% growth, Europe will grow at an even slower rate of 1-4% and Japan will move at 2-5% in the next four years, underscoring the importance of Asian markets, IMS stresses.